Aflac, the number one provider of supplemental insurance in the United States, and recognized six times by Ethisphere as one of the World’s Most Ethical Companies, is once again teaming with Macy’s to produce and sell the 2012 Aflac Holiday duck . This is the twelfth year that Aflac and Macy’s are selling the annual plush duck, with all net proceeds going to support research and treatment for childhood cancer.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58454-aflac-macys-annual-holiday-duck-design-pediatric-cancer-patient-atlanta
http://adultadhdtreatmentblog.com/adult-adhd-treatment/
Grownup ADHD treatment is highlighted via this write-up. Even although ADHD - attention deficit/hyperactivity problem - is usually associated with small children, it also affects adults and troubles them during their whole lifetime. According to various studies there are substantial percentages of adults struggling with ADHD. Out of the population of ten million nearly the low of 1 percent to high of six % suffers from ADHD.
The problems of Grownups suffering from ADHD are different from the children. Adults don
http://adultadhdtreatmentblog.com/adhd-alternative-treatment/
In recent years, study has brought to light some fairly startling details about using prescription medications to treat ADHD. For this reason, along with other people, many parents are now looking for ADHD alternative treatments for their children. Things like potentially serious side results, unknown long term effects and the increasing expenses of doctor prescribed medications are making an ADHD alternative therapy seem like a better idea each day. In this article, we
In recent years there has been a shift in the understanding of cancer. Immunotherapy with vaccines has been emerging as the most promising direction towards a decisive improvement of treatment outcomes.
The Dendritic Cell Vaccine has received FDA approval for prostate cancer and trials are now under way for a variety of other cancers. These vaccines are usually administered on their own.
To view Multimedia News Release, go to http://www.multivu.com/mnr/64654-issels-integrative-immunotherapy-for-standard-therapy-resistant-cancers
GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its U.S. subsidiary Greenwich Biosciences, announced today that The New England Journal of Medicine has published results from a Phase 3 study of Epidiolex® (cannabidiol) in children with Dravet syndrome.1 Epidiolex, GW’s lead product candidate and the potential first in a new category of anti-epileptic drugs, is a liquid formulation of purified, plant-derived cannabidiol (CBD), a non-psychoactive cannabinoid, which is being studied for the treatment of a number of rare, severe pediatric-onset epilepsy disorders. In the study, Epidiolex significantly reduced monthly convulsive seizure frequency compared to placebo in highly treatment-resistant children when added to existing treatment. Treatment with Epidiolex was generally well tolerated, with a safety profile consistent with prior open label experience.
To view the multimedia release go to:
https://www.multivu.com/players/uk/8109951-gw-pharmaceuticals-study-epidiolex/
Abbott announced today that the U.S. Food and Drug Administration has approved the company’s Absorb bioresorbable heart stent, making the first-of-its-kind medical device commercially available to treat people with coronary artery disease in the United States.
Absorb is the only fully dissolving stent approved for the treatment of coronary artery disease, which affects 15 million people in the United States and remains a leading cause of death worldwide, despite decades of therapeutic advances. While stents are traditionally made of metal, Abbott’s Absorb stent is made of a naturally dissolving material, similar to dissolving sutures. Absorb disappears completely in approximately three years, after it has done its job of keeping a clogged artery open and promoting healing of the treated artery segment. By contrast, metal stents are permanent implants that restrict vessel motion for the life of the person treated.
To view the multimedia release go to:
http://www.multivu.com/players/English/7826651-abbott-fda-approval-stent/
Federally funded research that provides a deep understanding of cancer is spurring advances against many types of the disease. With a strong bipartisan commitment from Congress to keep investment in biomedical research a national priority, we can accelerate our pace of progress and save more lives from cancer, according to the seventh annual American Association for Cancer Research (AACR) Cancer Progress Report, released today.
Basic research in the fields of immunology and cancer genetics has recently been harnessed to develop two new forms of cancer treatment: immunotherapy and precision medicine. As detailed in the report, the utility of these treatments is expanding rapidly. In May 2017, the U.S. Food and Drug Administration (FDA) heralded a new dawn for precision medicine when it approved the immunotherapeutic pembrolizumab (Keytruda) for treating patients with any solid tumor harboring specific genetic characteristics. This is the first anticancer therapeutic approved based on cancer biomarkers rather than the location in the body where the cancer originated.
To view the multimedia release go to:
https://www.multivu.com/players/English/8155051-aacr-cancer-progress-report-2017/
Federally funded research continues to spur progress against cancer; however, accelerating the pace of progress will require robust, sustained, and predictable annual funding increases for the National Institutes of Health (NIH), the National Cancer Institute (NCI), and the Food and Drug Administration (FDA). Additionally, strong financial support for the National Cancer Moonshot Initiative is required, according to the sixth annual American Association for Cancer Research (AACR) Cancer Progress Report, released today.
One of the most exciting new approaches to cancer treatment is cancer immunotherapy. As detailed in the report, the utility of immunotherapy is expanding rapidly. For example, on Aug. 1, 2015, one class of immunotherapeutics, checkpoint inhibitors, was initially approved for just two types of cancer—melanoma and lung cancer. As of Sept. 1, 2016, checkpoint inhibitors have been approved for treating six types of cancer—bladder cancer, head and neck cancer, Hodgkin lymphoma, kidney cancer, lung cancer, and melanoma.
To view the multimedia release go to:
http://www.multivu.com/players/English/7911951-aacr-2016-cancer-progress-report/
Adults over the age of 60 are at the greatest risk of atrial fibrillation (AF), a potentially life-threatening heart rhythm disorder. Yet, according to a recent survey conducted by the Heart Rhythm Society (HRS), more than 25 percent of Americans between the ages of 55 and 64 have never heard of AF. Today marks the kick-off of HRS’ second annual “A-Fib Feels Like” campaign to help educate Americans about the symptoms and warning signs associated with AF and encourage those who suffer from the disorder to talk to their doctors about their risks and potential treatment options.
To view Multimedia News Release, go to http://www.multivu.com/mnr/57735-a-fib-feels-like-campaign-warning-signs-atrial-fibrillation
With the introduction of Abbott's iDesign Dx system, U.S. ophthalmologists now have a diagnostic tool that can capture five optical measurements in one three-second scan to determine the patient's visual abnormalities. This highly advanced diagnostic tool measures the internal optics and surface of the eye more precisely than conventional methods, allowing doctors to fully evaluate imperfections that result in poor vision. Obtaining these measurements in one three-second scan enables ophthalmologists to screen patients more efficiently to determine if they are eligible for LASIK or other refractive surgery and to assist in diagnosis of other conditions.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/64467-abbott-idesign-dx-system-available-for-opthalmologists-and-patients
